At the coming Auto Expo, the audience will get the opportunity of meeting...
A recent study carried out by the researchers from the National Eye Institute in the United States has claimed that Avastin is slightly riskier as compared to Lucentis for the treatment of age-related macular degeneration (AMD). The new study is published in the New England Journal of Medicine.
Lucentis is more expensive as compared to Avastin and costs $2,000 per dose. The drug is approved by the US Food and Drug Administration (FDA) for the treatment of AMD. Avastin is manufactured by Roche Holding and cost about $50 for per dose. The researchers have also said that despite the side effects or the risk associated with the use of Avastin, both the drugs are equally effective.
The study involved more than 1,200 patients with age-related macular degeneration. The results of the examination found that Avastin was effective as Lucentis for the treatment of AMD though it was not approved by FDA.
The findings of the study also reveal that patients who were treated with Avastin were at a 30% higher risk of serious problems affecting the rest of the body as compared to those who were treated with Lucentis.
